Skip to main content
NIH funding notice RFA-DK-21-005

Immune Cell Engineering For Targeted Therapy And Disease Monitoring in Type 1 Diabetes (R01 Clinical Trial Not Allowed)

Closed on June 22, 2021.

Posted
February 19, 2021
Close date
June 22, 2021
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

7 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $5,410,683 in first-year total cost, median $791,321.

Most frequent study sections

  1. Special Emphasis Panel[ZDK1 GRB-J (J1)]7

Most frequent institutions

  1. BENAROYA RESEARCH INST AT VIRGINIA MASON1
  2. BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)1
  3. DANA-FARBER CANCER INST1
  4. STANFORD UNIVERSITY1
  5. UNIVERSITY OF ARIZONA1
Competing awards under RFA-DK-21-005 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2022Harnessing engineered T regulatory cells to promote beta cell health in T1D1R01DK132593-01BUCKNER, JANE HOYTRAWLINGS, DAVID JBENAROYA RESEARCH INST AT VIRGINIA MASON, WA$993,436ZDK1
2022Engineering 2nd generation 5MCARs to monitor and treat Type-I Diabetes1R01DK132537-01KUHNS, MICHAEL SSERWOLD, THOMAS FUNIVERSITY OF ARIZONA, AZ$841,657ZDK1
2022Engineering synthetic immune cells with modular sentinel and therapeutic functions for T1D1R01DK132547-01LIM, WENDELL AUNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA$830,753ZDK1
2022Engineered Immune Cells for T1D1R01DK132549-01MEYER, EVERETTSTANFORD UNIVERSITY, CA$791,321ZDK1
2022Engineering T cells to Promote Islet Transplant1R01DK132725-01DURAN-STRUUCK, RAIMONNAJI, ALIRILEY, JAMES L.UNIVERSITY OF PENNSYLVANIA, PA$780,000ZDK1
2022Precise targeting of T1D specific T cells using CAR and peptide-MHC chimeric antigen ligands1R01DK132576-01BIRNBAUM, MICHAELCETRULO, CURTIS LISANTEKENT, SALLY CHOATEWONG, WILSONBOSTON UNIVERSITY (CHARLES RIVER CAMPUS), MA$728,516ZDK1
2022Engineering dendritic cells to target islet antigen to pro-tolerogenic subsets for prevention and treatment of Type 1 Diabetes1R01DK132544-01AGUDO CANTERO, JUDITHDANA-FARBER CANCER INST, MA$445,000ZDK1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.